ALIMTA® (pemetrexed for injection) is indicated in combination with pembrolizumab (pembro) and platinum chemotherapy for the initial treatment of patients with nonsquamous (NS) metastatic non-small cell lung cancer (mNSCLC) with no EGFR or ALK genomic tumor aberrations.
Limitation of Use: ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.
ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor.
ALIMTA is contraindicated in patients who have a history of severe hypersensitivity reaction to pemetrexed.
For safety and dosing guidelines for ALIMTA, see complete Warnings and Precautions, Adverse Reactions, and Dosage and Administration sections in the fulland .
ALIMTA® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.